Key Points
-
CUT-like homeobox 1 (CUX1) undergoes loss-of-heterozygosity (LOH) and loss-of-function somatic point mutations in several cancers. As no mutations are found in the remaining allele, CUX1 seems to be a haploinsufficient tumour suppressor gene.
-
Copy number gains are much more frequent than losses in cancers arising from many different types of tissue, including cancers that have a high frequency of loss-of-function mutations. Increased CUX1 copy number and expression levels are associated with shorter disease-free survival.
-
The accumulated evidence suggests that decreased CUX1 expression facilitates tumour initiation, whereas increased CUX1 expression promotes tumorigenic progression.
-
One CUX1 protein isoform functions as an ancillary factor in base excision repair. Other CUX1 isoforms function as transcriptional repressors or activators, depending on promoter context.
-
Cellular functions of CUX1 that promote tumour development involve cell cycle progression, cell migration and invasion, resistance to apoptosis, promotion of bipolar mitosis in the presence of multiple centrosomes, accelerated repair of oxidative DNA damage and modulation of the tumour microenvironment.
-
Cellular functions of CUX1 that suppress tumour development include inhibition of the PI3K–AKT pathway and a direct role in base excision repair.
Abstract
CUT-like homeobox 1 (CUX1) is a homeobox gene that is implicated in both tumour suppression and progression. The accumulated evidence supports a model of haploinsufficiency whereby reduced CUX1 expression promotes tumour development. Paradoxically, increased CUX1 expression is associated with tumour progression, and ectopic CUX1 expression in transgenic mice increases tumour burden in several tissues. One CUX1 isoform functions as an ancillary factor in base excision repair and the other CUX1 isoforms act as transcriptional activators or repressors. Several transcriptional targets and cellular functions of CUX1 affect tumorigenesis; however, we have yet to develop a mechanistic framework to reconcile the opposite roles of CUX1 in cancer protection and progression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Blochlinger, K., Bodmer, R., Jack, J., Jan, L. Y. & Jan, Y. N. Primary structure and expression of a product from cut, a locus involved in specifying sensory organ identity in Drosophila. Nature 333, 629–635 (1988).
Neufeld, E. J., Skalnik, D. G., Lievens, P. M. & Orkin, S. H. Human CCAAT displacement protein is homologous to the Drosophila homeoprotein, cut. Nature Genet. 1, 50–55 (1992).
Schoenmakers, E. F. et al. Identification of CUX1 as the recurrent chromosomal band 7q22 target gene in human uterine leiomyoma. Genes Chromosomes Cancer 52, 11–23 (2013).
Jerez, A. et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 119, 6109–6117 (2012).
McNerney, M. E. et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood 121, 975–983 (2013).
Klampfl, T. et al. Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood 118, 167–176 (2011).
Hindersin, S., Niemeyer, C. M., Germing, U., Göbel, U. & Kratz, C. P. Mutation analysis of CUTL1 in childhood myeloid neoplasias with monosomy 7. Leukemia Res. 31, 1323–1324 (2007).
Patrikis, M. et al. Mutation analysis of CDP, TP53, and KRAS in uterine leiomyomas. Mol. Carcinogen. 37, 61–64 (2003).
Moon, N. S. et al. Expression of N-terminally truncated isoforms of CDP/CUX is increased in human uterine leiomyomas. Int. J. Cancer 100, 429–432 (2002).
Thoennissen, N. H. et al. Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms. Blood 115, 2882–2890 (2010). References 3, 6 and 10 provide compelling evidence that CUX1 is the target of LOH at 7q22.1. Moreover, references 4 and 5 show that CUX1 mRNA and protein expression was reduced approximately twofold in leukaemic cells of affected patients.
Wong, C. C. et al. Inactivating CUX1 mutations promote tumorigenesis. Nature Genet. 46, 33–38 (2014). This study shows that CUX1 harbours inactivating somatic mutations in a proportion of human cancers and provides functional evidence that inactivation of ct in D. melanogaster or Cux1 in mice promotes tumour development.
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Michl, P. et al. CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521–532 (2005). This study is the first to show that CUX1 mRNA and protein expression is increased by TGFβ and is required for TGFβ-induced cell migration and invasion.
Ripka, S. et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut 59, 1101–1110 (2010). This study shows that CUX1 expression is stimulated downstream of the PI3K–AKT pathway and confers resistance to apoptosis.
Ledford, A. W. et al. Deregulated expression of the homeobox gene Cux-1 in transgenic mice results in downregulation of p27kip1 expression during nephrogenesis, glomerular abnormalities, and multiorgan hyperplasia. Dev. Biol. 245, 157–171 (2002).
Cadieux, C. et al. Transgenic mice expressing the p75 CCAAT-displacement protein/Cut homeobox isoform develop a myeloproliferative disease-like myeloid leukemia. Cancer Res. 66, 9492–9501 (2006).
Cadieux, C. et al. Mouse mammary tumor virus p75 and p110 CUX1 transgenic mice develop mammary tumors of various histologic types. Cancer Res. 69, 7188–7197 (2009). This study shows that increased expression of either p75 CUX1 or p110 CUX1 in mammary epithelial cells causes mammary tumours of various histological types.
Ramdzan, Z. M. et al. RAS transformation requires CUX1-dependent repair of oxidative DNA damage. PLoS Biol. 12, e1001807 (2014). This study shows that p200 CUX1 accelerates repair of oxidative DNA damage, prevents RAS-induced senescence and allows the emergence of tumours with spontaneous activating mutations in Kras . CUX1 knockdown is shown to be synthetic lethal in KRAS- and HRAS-driven human cancer cells.
Sansregret, L. et al. Cut homeobox 1 causes chromosomal instability by promoting bipolar division after cytokinesis failure. Proc. Natl Acad. Sci. USA 108, 1949–1954 (2011). This study shows that p110 CUX1 activates expression of genes involved in the spindle assembly checkpoint and promotes bipolar mitosis in cells with more than two centrosomes. However, frequent merotelic chromosome attachments lead to aneuploidy and rapidly generate populations of genetic variants from which tumour cells emerge.
Siam, R. et al. Transcriptional activation of the Lats1 tumor suppressor gene in tumors of CUX1 transgenic mice. Mol. Cancer 8, 60–70 (2009).
Sansregret, L. et al. The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol. Cell. Biol. 26, 2441–2455 (2006).
Truscott, M. et al. Carboxyl-terminal proteolytic processing of CUX1 by a caspase enables transcriptional activation in proliferating cells. J. Biol. Chem. 282, 30216–30226 (2007).
Vadnais, C. et al. CUX1 transcription factor is required for optimal ATM/ATR-mediated responses to DNA damage. Nucleic Acids Res. 40, 4483–4495 (2012).
Goulet, B. et al. Characterization of a tissue-specific CDP/Cux isoform, 75, activated in breast tumor cells. Cancer Res. 62, 6625–6633 (2002).
Moon, N. S. et al. S Phase-specific proteolytic cleavage is required to activate stable DNA binding by the CDP/Cut homeodomain protein. Mol. Cell. Biol. 21, 6332–6345 (2001).
Vanden Heuvel, G. B., Quaggin, S. E. & Igarashi, P. A. Unique variant of a homeobox gene related to Drosophila Cut is expressed in mouse testis. Biol. Reprod. 55, 731–739 (1996).
Maitra, U., Seo, J., Lozano, M. M. & Dudley, J. P. Differentiation-induced cleavage of Cutl1/CDP generates a novel dominant-negative isoform that regulates mammary gene expression. Mol. Cell. Biol. 26, 7466–7478 (2006).
Sansregret, L. & Nepveu, A. The multiple roles of CUX1: Insights from mouse models and cell-based assays. Gene 412, 84–94 (2008).
Skalnik, D. G., Strauss, E. C. & Orkin, S. H. CCAAT displacement protein as a repressor of the myelomonocytic-specific gp91-phox gene promoter. J. Biol. Chem. 266, 16736–16744 (1991).
Lievens, P. M. J., Donady, J. J., Tufarelli, C. & Neufeld, E. J. Repressor activity of CCAAT displacement protein in HL-60 myeloid leukemia cells. J. Biol. Chem. 270, 12745–12750 (1995).
Superti-Furga, G., Barberis, A., Schreiber, E. & Busslinger, M. The protein CDP, but not CP1, Footprints on the CCAAT region of the g-globulin gene in unfractionated B-cell extracts. Biochim. Biophys. Acta 1007, 237–242 (1989).
Stunkel, W., Huang, Z., Tan, S. H., O'Connor, M. J. & Bernard, H. U. Nuclear matrix attachment regions of human papillomavirus type 16 repress or activate the E6 promoter, depending on the physical state of the viral DNA. J. Virol. 74, 2489–2501 (2000).
Pattison, S., Skalnik, D. G. & Roman, A. Ccaat Displacement protein, a regulator of differentiation-specific gene expression, binds a negative regulatory element within the 5′ end of the human papillomavirus type 6 long control region. J. Virol. 71, 2013–2022 (1997).
Cubelos, B. et al. Cux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layer neurons of the cortex. Neuron 66, 523–535 (2010).
Ellis, T. et al. The transcriptional repressor CDP (Cutl1) is essential for epithelial cell differentiation of the lung and the hair follicle. Genes Dev. 15, 2307–2319 (2001).
Moon, N. S., Berube, G. & Nepveu, A. CCAAT displacement activity involves Cut repeats 1 and 2, not the Cut homeodomain. J. Biol. Chem. 275, 31325–31334 (2000).
Mailly, F. et al. The human cut homeodomain protein can repress gene expression by two distinct mechanisms: active repression and competition for binding site occupancy. Mol. Cell. Biol. 16, 5346–5357 (1996).
Dianov, G. L. & Hubscher, U. Mammalian base excision repair: the forgotten archangel. Nucleic Acids Res. 41, 3483–3490 (2013).
Vadnais, C. et al. Long-range transcriptional regulation by the p110 CUX1 homeodomain protein on the ENCODE array. BMC Genomics 14, 258 (2013).
Goulet, B. et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S Phase and processes the CDP/Cux transcription factor. Mol. Cell 14, 207–219 (2004).
Harada, R. et al. Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes. Nucleic Acids Res. 36, 189–202 (2008).
Kedinger, V. et al. p110 CUX1 homeodomain protein stimulates cell migration and invasion in part through a regulatory cascade culminating in the repression of E-cadherin and occludin. J. Biol. Chem. 284, 27701–27711 (2009).
Kuhnemuth, B. et al. CUX1 modulates polarization of tumor-associated macrophages by antagonizing NF-κB signaling. Oncogene http://dx.doi.org/10.1038/onc.2013.530 (2013). This study presents results showing that TGFβ stimulates the expression of CUX1 in tumour-associated macrophages. In turn, CUX1 regulates cytokine expression to modulate the tumour microenvironment.
Ozisik, Y. Y., Meloni, A. M., Surti, U. & Sandberg, A. A. Deletion 7q22 in uterine leiomyoma. A cytogenetic review. Cancer Genet. Cytogenet. 71, 1–6 (1993).
Zeng, W. R. et al. Loss of heterozygosity and reduced expression of the CUTL1 gene in uterine leiomyomas. Oncogene 14, 2355–2365 (1997).
Zeng, W. R. et al. Refined mapping of the region of loss of heterozygosity on the long arm of chromosome 7 in human breast cancer defines the location of a second tumor suppressor gene at 7q22 in the region of the CUTL1 gene. Oncogene 18, 2015–2021 (1999).
Pedersen-Bjergaard, J., Andersen, M. T. & Andersen, M. K. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Hematology Am. Soc. Hematol. Educ.Program 392–397 (2007).
Zhang, Y. & Rowley, J. D. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair 5, 1282–1297 (2006).
Thoennissen, N. H. et al. Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. Am. J. Hematol. 86, 703–705 (2011).
Luong, M. X. et al. Genetic ablation of the CDP/Cux protein C terminus results in hair cycle defects and reduced male fertility. Mol. Cell. Biol. 22, 1424–1437 (2002).
Sinclair, A. M. et al. Lymphoid apoptosis and myeloid hyperplasia in CCAAT displacement protein mutant mice. Blood 98, 3658–3667 (2001).
Adzhubei, I. A. et al. A method and server for predicting damaging missense mutations. Nature Methods 7, 248–249 (2010).
Kumar, P., Henikoff, S. & Ng, P. C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature Protoc. 4, 1073–1081 (2009).
Collier, L. S., Carlson, C. M., Ravimohan, S., Dupuy, A. J. & Largaespada, D. A. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 436, 272–276 (2005).
Glosli, H. et al. Effects of hTNFα expression in T cells on haematopoiesis in transgenic mice. Eur. J. Haematol. 63, 50–60 (1999).
Lievens, P. M., Tufarelli, C., Donady, J. J., Stagg, A. & Neufeld, E. J. CASP, a novel, highly conserved alternative-splicing product of the CDP/cut/cux gene, lacks cut-repeat and homeo DNA-binding domains, and interacts with full-length CDP in vitro. Gene 197, 73–81 (1997).
Gillingham, A. K., Pfeifer, A. C. & Munro, S. CASP, the alternatively spliced product of the gene encoding the CCAAT-displacement protein transcription factor, is a Golgi membrane protein related to giantin. Mol. Biol. Cell 13, 3761–3774 (2002).
Ripka, S. et al. WNT5A—target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis 28, 1178–1187 (2007).
Brantley, J. G., Sharma, M., Alcalay, N. I. & Heuvel, G. B. V. Cux-1 transgenic mice develop glomerulosclerosis and interstitial fibrosis. Kidney Int. 63, 1240–1248 (2003).
Vanden Heuvel, G. B. et al. Hepatomegaly in transgenic mice expressing the homeobox gene Cux-1. Mol. Carcinog. 43, 18–30 (2005).
Cadieux, C. et al. Polycystic kidneys caused by sustained expression of Cux1 isoform p75. J. Biol. Chem. 283, 13817–13824 (2008).
Truscott, M. Harada, R., Vadnais, C., Robert, F. & Nepveu, A. p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes. Mol. Cell. Biol. 28, 3127–3138 (2008).
Seguin, L. et al. CUX1 and E2F1 regulate coordinated expression of the mitotic complex genes Ect2, MgcRacGAP, and MKLP1 in S phase. Mol. Cell. Biol. 29, 570–581 (2009).
Aleksic, T. et al. CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation. Oncogene 26, 5939–5949 (2007).
Kedinger, V. & Nepveu, A. The roles of CUX1 homeodomain proteins in the establishment of a transcriptional program required for cell migration and invasion. Cell Adh. Migr. 4, 348–352 (2010).
Michl, P. & Downward, J. CUTL1: a key mediator of TGFβ-induced tumor invasion. Cell Cycle 5, 132–134 (2006).
Hulea, L. & Nepveu, A. CUX1 transcription factors: from biochemical activities and cell-based assays to mouse models and human diseases. Gene 497, 18–26 (2012).
van Wijnen, A. J., Wright, K. L., Lian, J. B., Stein, J. L. & Stein, G. S. Human H4 histone gene transcription requires the proliferation-specific nuclear factor HiNF-D. Auxiliary roles for HiNF-C (Sp1-like) and HiNF-A (high mobility group-like). J. Biol. Chem. 264, 15034–15042 (1989).
Holthuis, J. et al. Tumor cells exhibit deregulation of the cell cycle histone gene promoter factor HiNF-D. Science 247, 1454–1457 (1990).
van Wijnen, A. J. et al. CDP/cut is the DNA-binding subunit of histone gene transcription factor HiNF-D: a mechanism for gene regulation at the G1/S phase cell cycle transition point independent of transcription factor E2F. Proc. Natl Acad. Sci. USA 93, 11516–11521 (1996).
Truscott, M. et al. CDP/Cux stimulates transcription from the DNA polymerase α gene promoter. Mol. Cell. Biol. 23, 3013–3028 (2003).
Coqueret, O., Berube, G. & Nepveu, A. The mammalian Cut homeodomain protein functions as a cell-cycle-dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase. EMBO J. 17, 4680–4694 (1998).
Sharma, M., Fopma, A., Brantley, J. G. & Vanden Heuvel, G. B. Coexpression of Cux-1 and Notch signaling pathway components during kidney development. Dev. Dyn. 231, 828–838 (2004).
Sharma, M. et al. Differential expression of Cux-1 and p21 in polycystic kidneys from Pkd1 null and cpk mice. Kidney Int. 67, 432–442 (2005).
Sharma, M. et al. The homeodomain protein Cux1 interacts with Grg4 to repress p27 kip1 expression during kidney development. Gene 439, 87–94 (2009).
He, X. et al. PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. Cancer Res. 68, 5591–5598 (2008).
Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823–837 (2009).
Silkworth, W. T., Nardi, I. K., Scholl, L. M. & Cimini, D. Multipolar spindle pole coalescence is a major source of kinetochore mis-attachment and chromosome mis-segregation in cancer cells. PLoS ONE 4, e6564 (2009).
Ganem, N. J., Godinho, S. A. & Pellman, D. A mechanism linking extra centrosomes to chromosomal instability. Nature 460, 278–282 (2009).
Nigg, E. A. Centrosome aberrations: cause or consequence of cancer progression? Nature Rev. Cancer 2, 815–825 (2002).
Storchova, Z. & Kuffer, C. The consequences of tetraploidy and aneuploidy. J. Cell Sci. 121, 3859–3866 (2008).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl. J. Med. 366, 883–892 (2012).
Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009).
Curtin, N. J. DNA repair dysregulation from cancer driver to therapeutic target. Nature Rev. Cancer 12, 801–817 (2012).
Shaheen, M., Allen, C., Nickoloff, J. A. & Hromas, R. Synthetic lethality: exploiting the addiction of cancer to DNA repair. Blood 117, 6074–6082 (2011).
Acknowledgements
This work was supported by Grant number MOP-98010 from the Canadian Institutes of Health Research (CIHR) to A.N.; Z.M.R. was supported by the Fonds de la recherche du Québec-Santé (FRQS). This Review is dedicated to the memory of Rosalind Goodman.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Glossary
- Loss-of-heterozygosity
-
(LOH). Loss of one allele of a gene when the original two alleles can be distinguished. This is common for tumour suppressor genes when the other allele is mutated, although it may occur without mutation of the remaining allele.
- Haploinsufficient
-
Describing loss or mutagenic inactivation of a single allele of a tumour suppressor gene that hastens tumorigenicity.
- Non-oncogene addictions
-
The concept of 'non-oncogene addiction' describes the heightened dependency of tumour cells on the normal cellular functions of certain genes that are not themselves classical oncogenes.
- The Knudson two-hit model
-
A model that stipulates that inactivation of a tumour suppressor gene requires two events: the loss of one allele, in a process called loss-of-heterozygosity (LOH); and the occurrence of inactivating mutation in the second allele. However, a dominant-negative mutation may be sufficient to inactivate the function of a tumour suppressor, as in the case of TP53.
- Glomerulosclerosis
-
The scarring or hardening of the glomeruli, which are the blood vessels in the kidney.
- Interstitial fibrosis
-
A disease that is characterized by increased proliferation and accumulation of extracellular matrix.
- Merotelic chromosome attachments
-
These attachments occur when a single kinetochore is attached to microtubules emanating from both spindle poles. If not corrected, merotelic attachments may result in whole chromosome missegregation and aneuploidy.
- Synthetic lethal
-
A situation in which the inactivation of a pathway by a genetic means is lethal to cells that harbour a mutation in an different pathway but is not overly detrimental to normal cells.
Rights and permissions
About this article
Cite this article
Ramdzan, Z., Nepveu, A. CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers. Nat Rev Cancer 14, 673–682 (2014). https://doi.org/10.1038/nrc3805
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc3805
This article is cited by
-
Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells
Oncogene (2023)
-
Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets
Leukemia (2023)
-
Genome-wide significant risk loci for mood disorders in the Old Order Amish founder population
Molecular Psychiatry (2023)
-
CUX1-related neurodevelopmental disorder: deep insights into phenotype-genotype spectrum and underlying pathology
European Journal of Human Genetics (2023)
-
Thorough statistical analyses of breast cancer co-methylation patterns
BMC Genomic Data (2022)